VKTX
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) has 5 SEC Form 4 filings (8 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Aug 7, 2026.
Insiders have net sold $6.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Brian Lian
- Employees:53
- HQ:San Diego, CA, US
- IPO:2015-04-28
Insider Buying
$150K
reported purchases (SEC code P)
Insider Selling
$6.3M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$4.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Lian BrianFirst filing | President & CEO | Sale | 148,517 | $4.9M | Jul 30 | SEC ↗ |
ZANTE GREGFirst filing | Chief Financial Officer | Sale | 21,217 | $710K | Jul 30 | SEC ↗ |
Mancini MariannaFirst filing | Chief Operating Officer | Sale | 18,217 | $610K | Jul 30 | SEC ↗ |
Aubuchon Neil WilliamFirst filing | Chief Commercial Officer | Purchase | 4,475 | $150K | Mar 10 | SEC ↗ |
Related companies
Viking Therapeutics, Inc. is in the Healthcare sector.